Navigation Links
Breast Radiation After Lumpectomy Saves Lives: Study
Date:10/20/2011

By Amanda Gardner
HealthDay Reporter

WEDNESDAY, Oct. 19 (HealthDay News) -- Women with breast cancer who undergo radiation after a lumpectomy have significantly fewer recurrences and, consequently, greater odds of survival than women who forgo radiation, new research says.

The study also noted no long-term adverse effects from radiation after this breast-conserving surgery, as deaths from any cause were also reduced substantially.

"For the first time, this showed this important linkage between using radiation to avoid local recurrence and improving long-term survival," said Dr. Jay Harris, chairman of radiation oncology at Dana-Farber Cancer Institute and Brigham & Women's Hospital in Boston. "Up until 2005, the prevailing attitude in the U.S. was that radiation did not have an impact on improving long-term survival and was strictly to reduce local recurrence."

Giving radiotherapy after breast-conserving treatment is already common practice, said Dr. Shelly Hayes, a radiation oncologist with Fox Chase Cancer Center in Philadelphia. The point is to destroy any stray cells in the affected breast.

The findings echo the results of a landmark 2005 paper that involved fewer women and shorter follow-up. They should help erase any lingering doubts among skeptics, experts said.

"It is going to be very helpful to see updated results with lots more patients, lots more follow-up and this is very substantial improvement in long-term outcome," Harris said.

Here, the authors assessed data on almost 11,000 women in 17 randomized trials that compared radiation with no radiation after lumpectomy.

The authors took the unusual step of including both published and unpublished trials, making "the data very reliable," said Harris.

Overall, irradiating the affected breast halved recurrence rates and cut the mortality rate by one-sixth, the researchers said.

After 10 years, 19 percent of women who had undergone radiation had had a recurrence compared with almost twice as many -- 35 percent -- in the non-radiation group.

And 15 years after diagnosis, 25 percent of women with radiation were alive, vs. 21 percent in the control group. At that time, the absolute risk reduction in all-cause mortality was 3 percent, the study found.

The numbers varied according to age, grade of tumor, estrogen-receptor status, whether the patient had taken the estrogen-suppressing drug tamoxifen and how extensive the surgery had been.

"The magnitude of the benefit got smaller with more favorable factors, but there were benefits in every subgroup, which translated into benefit in terms of recurrence risk, which translated into overall survival," Hayes said.

"Across the board, no matter what those features were, women benefited from radiation," Hayes said.

For some time, doctors have wondered whether radiation was really necessary for all women, said study co-author Sarah Darby, professor of medical statistics at the University of Oxford in England.

"These findings will enable both doctors and patients to have a better idea of the benefit that is likely to be gained from radiotherapy on a patient-by-patient basis," she said.

More information

The U.S. National Cancer Institute has more on breast cancer treatments.

SOURCES: Sarah Darby, Ph.D., professor, medical statistics, University of Oxford, England; Shelly Hayes, M.D., radiation oncologist, Fox Chase Cancer Center, Philadelphia; Jay R. Harris, M.D., professor and chairman, radiation oncology, Dana-Farber Cancer Institute and Brigham & Women's Hospital, Boston; Oct. 20, 2011, The Lancet, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Paxil Blocks Tamoxifen, Lowers Survival Odds Against Breast Cancer
2. Low forms of cyclin E reduce breast cancer drugs effectiveness
3. Racial disparities persist in the diagnosis of advanced breast cancer and colon cancer in the U.S.
4. For Some Breast Cancer Patients, Shorter Radiation Works Well
5. Short-term radiation therapy successful on breast cancer
6. Few Women at High Risk for Breast Cancer Take Tamoxifen
7. Hormone May Prevent Aggressive Breast Cancer
8. MSU researcher linking breast cancer patients with alternative therapies
9. MRI May Not Add Value to Routine Breast Cancer Care
10. Breast Cancer Stats Differ Racially Despite Similar Mammogram Rates
11. Businesses Rally Big Efforts to Benefit the Susan G. Komen Phoenix Affiliates Fight Against Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Breast Radiation After Lumpectomy Saves Lives: Study
(Date:1/20/2017)... ... January 20, 2017 , ... Source Vitál Apothecary, a skin and body care ... announced the company had a successful visit to the 2017 ECRM Diet, Vitamin & ... that work in the nutritional, sports and health industries a chance to meet in ...
(Date:1/20/2017)... Florida (PRWEB) , ... January 20, 2017 , ... Lice ... head lice cases in families with school-aged children since the holiday season. , ... the holidays with their families, sharing hugs and taking photos, which is the head-to-head ...
(Date:1/20/2017)... ... ... Michael and Betsy Brauser celebrated 5 years of Betsy’s participation in a ... has been life-saving as she has been on the trial for more than six ... ovarian cancer in 2009. She underwent standard chemotherapy but a year later went to ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... “Mary Magdalene: ... the mysterious life of the woman who witnessed Jesus Christ firsthand. “Mary Magdalene: Grace ... denizen, who spent her career as an educator interacting with countless women who had ...
(Date:1/20/2017)... , ... January 20, 2017 , ... “I Forgive You”: a fine examination of ... Forgive You” is the creation of published author, Stephen Miller, who, for over ten long ... gracefully given to him. Born in Trinidad and Tobago, he has been serving the Lord ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... Jan. 19, 2017 Report Details ... Alzheimer,s ... Leading Companies – our new study reveals trends, R&D ... and events affecting the Alzheimer,s disease therapeutics and diagnostics ... these key questions: - How is the Alzheimer,s disease ...
(Date:1/19/2017)... Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, Serotonin Receptor Agonists, Sympathomimetic-GABA Receptor ... market is expected to grow at a CAGR of 27.1% ... 38.7% in the second half of the forecast period. The market ... to 2027. The market is estimated at $1,058 million in 2016, ... ...
(Date:1/19/2017)... LONDON , January 19, 2017 ... Grothey ; European Oncology & Haematology, 2016;12(Suppl 2):3-8; ... ... http://photos.prnewswire.com/prnh/20151014/276718LOGO) Published recently in ... the peer-reviewed journal from touchONCOLOGY, an article by ...
Breaking Medicine Technology: